ABL1 (H396P)
Sign in to save this workspaceABL1 · Variant type: point · HGVS: p.H396P
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Axitinib | 97.8% | 2.2% | 93.23 |
| 2 | Nintedanib | 97.8% | 2.2% | 90.23 |
| 3 | Bosutinib | 97.1% | 2.9% | 87.22 |
| 4 | Tivozanib | 97.0% | 3.0% | 92.42 |
| 5 | Nilotinib | 96.2% | 3.8% | 96.49 |
| 6 | Vandetanib | 96.1% | 3.9% | 95.74 |
| 7 | Ponatinib | 95.1% | 4.9% | 78.23 |
| 8 | Dasatinib | 95.0% | 5.0% | 87.97 |
| 9 | Pacritinib | 94.0% | 6.0% | 88.64 |
| 10 | Repotrectinib | 93.4% | 6.6% | 84.21 |
| 11 | Crizotinib | 91.9% | 8.1% | 91.39 |
| 12 | Canertinib | 90.6% | 9.4% | 96.49 |
| 13 | Erdafitinib | 90.1% | 9.9% | 95.71 |
| 14 | Brigatinib | 84.4% | 15.6% | 82.96 |
| 15 | Imatinib | 80.7% | 19.3% | 99.00 |
| 16 | Fedratinib | 75.0% | 25.0% | 96.21 |
| 17 | Lenvatinib | 74.6% | 25.4% | 97.74 |
| 18 | Erlotinib | 73.6% | 26.4% | 99.75 |
| 19 | Sunitinib | 72.5% | 27.5% | 91.73 |
| 20 | Dacomitinib | 72.0% | 28.0% | 97.99 |
| 21 | Ripretinib | 70.3% | 29.7% | 92.95 |
| 22 | Selpercatinib | 64.5% | 35.5% | 96.72 |
| 23 | Entrectinib | 63.8% | 36.2% | 93.69 |
| 24 | Pazopanib | 57.4% | 42.6% | 97.49 |
| 25 | Gilteritinib | 54.3% | 45.7% | 88.97 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Axitinib | 97.8% | 99.4% | -1.6% |
| Nintedanib | 97.8% | 99.9% | -2.1% |
| Bosutinib | 97.1% | 99.7% | -2.6% |
| Tivozanib | 97.0% | 95.8% | +1.2% |
| Nilotinib | 96.2% | 98.0% | -1.8% |
| Vandetanib | 96.1% | 95.7% | +0.3% |
| Ponatinib | 95.1% | 100.0% | -4.9% |
| Dasatinib | 95.0% | 98.6% | -3.6% |
| Pacritinib | 94.0% | 92.0% | +1.9% |
| Repotrectinib | 93.4% | 93.6% | -0.2% |
| Crizotinib | 91.9% | 97.0% | -5.1% |
| Canertinib | 90.6% | 91.6% | -0.9% |
| Erdafitinib | 90.1% | 90.9% | -0.8% |
| Brigatinib | 84.4% | 82.8% | +1.5% |
| Imatinib | 80.7% | 86.2% | -5.5% |
| Fedratinib | 75.0% | 82.7% | -7.7% |
| Lenvatinib | 74.6% | 76.3% | -1.7% |
| Erlotinib | 73.6% | — | — |
| Sunitinib | 72.5% | — | — |
| Dacomitinib | 72.0% | 80.8% | -8.8% |
| Ripretinib | 70.3% | 82.9% | -12.6% |
| Selpercatinib | 64.5% | — | — |
| Entrectinib | 63.8% | — | — |
| Pazopanib | 57.4% | 77.5% | -20.1% |
| Gilteritinib | 54.3% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| lymphoid_neoplasm_haematopoietic_and_lymphoid_tissue | Blood/Lymphatic System | ref |
| haematopoietic_neoplasm_haematopoietic_and_lymphoid_tissue | Blood/Lymphatic System | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 41.0ms